Loading...
NPI 1649571407 · Port Jefferson Station, NY · Hematology (Pathology) Physician
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Riem Badr is a hematology (pathology) physician provider located in Port Jefferson Station, New York. This profile covers 96 Medicare and 10 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Individual |
| Organization | Riem Badr |
| Address | 1500 Route 112 Bldg 4 |
| City | Port Jefferson Station |
| State | NY |
| ZIP | 11776 |
| Taxonomy | Hematology (Pathology) Physician |
| NPI Enumerated | November 10, 2010 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $8M |
| Medicaid | $2.2K |
Payer mix is effectively single-payer Medicare: the provider reports Total Medicare revenue of $8M versus Total Medicaid revenue of $2.2K, so Medicaid is commercially immaterial to overall revenue. The precomputed share shows the top 3 Medicare codes account for 67.0% of Medicare revenue while the top 3 Medicaid codes account for 100.0% of Medicaid revenue, underscoring the extreme imbalance between the two payers for this NPI.
Medicare revenue is highly concentrated in molecular infectious-agent testing: the three highest-revenue Medicare codes are 87798 ($2.8M, 36.3%), 87801 ($1.3M, 16.7%), and 87481 ($1.1M, 14.0%), and those three codes together make up the precomputed 67.0% share of this provider’s Medicare revenue. This concentration indicates the business is driven primarily by amplified nucleic acid probe testing rather than by broad routine lab panels.
The provider’s code mix indicates a service line combining high-volume molecular infectious testing with specialized pathology and cytogenetic interpretation. High-volume molecular codes such as 87798 (81.9K claims, $34 avg paid/claim), 87801 (18.6K claims, $69 avg paid/claim) and 87481 (31.7K claims, $34 avg paid/claim) coexist with in situ hybridization and flow cytometry interpretation codes (e.g., 88377, 88369, 88185/88189), which suggests a lab operation performing both large-scale infectious nucleic acid assays and higher-complexity pathology reads.
National competitive standing shows multiple high-percentile outlier positions on Medicare: 87801 ranks #7 of 561 providers nationally (99th percentile; extreme outlier) and 87481 ranks #10 of 1117 (99th percentile; extreme outlier), while 87798 ranks #24 of 1319 (98th percentile; notably above typical national volume). Several other pathology and flow-cytometry codes also sit at very high percentiles (for example, 88369 ranks #1 of 148 providers nationally, 100th percentile; extreme outlier), indicating this provider is a major national-volume participant for several specialized tests.
High-value pathology/in situ codes contribute disproportionately to per-claim revenue even if they are smaller by claim count: 88377 accounted for $579.9K (7.6% of Medicare revenue) with a $382 avg paid/claim, 88369 contributed $146.5K (1.9%) at $117 avg paid/claim, and 88368 added $67.3K (0.9%) at $134 avg paid/claim. The mix of relatively high per-claim payments for ISH/pathology interpretations plus large-volume molecular testing suggests a dual revenue stream of high-throughput assays and specialized, higher-reimbursement interpretive services.
Medicaid activity is negligible and concentrated: the top Medicaid code 88189 represents $1.8K (86.0% of this provider’s Medicaid revenue) and the next-largest Medicaid contributor is 87651 at $301 (14.0%). In-state ranks for these Medicaid codes are low (for example, 88189 ranks #24 of 30 in-state), indicating the provider is not a leading Medicaid performer in New York and that its Medicaid footprint is minimal compared to Medicare.
Tenure and operational scale align with sustained high-volume Medicare work: the NPI was enumerated on 2010-11-10 (~16 years ago), and the Medicare claims counts include very large volumes for key molecular codes (e.g., 87798 with 81.9K claims, 87481 with 31.7K claims). This longevity plus the large claim counts supports the interpretation of an established laboratory/pathology operation with ongoing high throughput.
Revenue and reimbursement profile imply sensitivity to Medicare molecular-pathology policy and demand shifts: because 67.0% of Medicare revenue is concentrated in the top three codes and Medicaid revenue is essentially immaterial, changes in Medicare coverage, coding, or pricing for amplified probe techniques and high-complexity pathology interpretation would have outsized impact on this provider’s topline. The provider’s competitive strength at the national level for several codes increases scale advantages but also concentrates exposure in a narrow set of high-volume services.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
96 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 81,880 | $30 | $2.8M |
| 87801 | The lab analyst performs a test for multiple infectious agents using amplified nucleic acid probe technique. | 18,570 | $70 | $1.3M |
| 87481 | The lab analyst performs a test for Candida species using amplified nucleic acid probe technique. | 31,710 | $30 | $1.1M |
| 88377 | The lab analyst applies a single multiplex in situ hybridization probe stain on a slide or slides prepared from a single patient specimen, such as tumor tissue. Then a qualified provider, typically a… | 1,520 | $380 | $579.9K |
| 88185 | The lab analyst performs the technical component of a flow cytometry procedure using cell surface, cytoplasmic, or nuclear markers to characterize cells and aid clinicians in diagnosing patients with… | 12,990 | $20 | $298.7K |
| 87640 | The lab analyst performs the technical lab test to look for Staphylococcus aureus nucleic acid using an amplified probe technique. | 6,350 | $30 | $216K |
| 87653 | The lab analyst performs a test for Streptococcus, group B, using amplified nucleic acid probe technique. The amplified probe provides a rapid means to assess colonization by Streptococcus, group B,… | 6,350 | $30 | $215.8K |
| 87500 | The lab analyst performs a test for vancomycin resistance in an infectious organism’s nucleic acid using amplified probe technique. VRE, vancomycin resistant enterococcus, is the most common organism… | 6,190 | $30 | $210.5K |
| 87651 | The lab analyst performs a test for the bacteria Streptococcus, group A, using amplified nucleic acid probe technique. Strep A commonly causes acute pharyngitis, or strep throat. | 5,850 | $30 | $198.8K |
| 88189 | The clinician, typically a pathologist, interprets flow cytometry results of 16 or more markers. | 2,460 | $70 | $182K |
Showing 1–10 of 96
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 96 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
10 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 88189 | The clinician, typically a pathologist, interprets flow cytometry results of 16 or more markers. | 20 | $80 | $1.8K |
| 87651 | The lab analyst performs a test for the bacteria Streptococcus, group A, using amplified nucleic acid probe technique. Strep A commonly causes acute pharyngitis, or strep throat. | 40 | $10 | $300 |
| 80053 | The lab analyst performs a comprehensive metabolic panel, or CMP test in which he measures the blood level of 14 chemicals the code descriptor lists for the panel. | 10 | $0 | $0 |
| 85025 | A complete blood count (better known as a CBC) is a blood test request by a doctor that provides detailed information about various types of cells in a patient's blood. Usually a pathologist or a… | 10 | $0 | $0 |
| 87481 | The lab analyst performs a test for Candida species using amplified nucleic acid probe technique. | 30 | $0 | $0 |
| 87500 | The lab analyst performs a test for vancomycin resistance in an infectious organism’s nucleic acid using amplified probe technique. VRE, vancomycin resistant enterococcus, is the most common organism… | 30 | $0 | $0 |
| 87640 | The lab analyst performs the technical lab test to look for Staphylococcus aureus nucleic acid using an amplified probe technique. | 30 | $0 | $0 |
| 87653 | The lab analyst performs a test for Streptococcus, group B, using amplified nucleic acid probe technique. The amplified probe provides a rapid means to assess colonization by Streptococcus, group B,… | 30 | $0 | $0 |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 30 | $0 | $0 |
| 87801 | The lab analyst performs a test for multiple infectious agents using amplified nucleic acid probe technique. | 30 | $0 | $0 |
How this provider's Medicaid billing volume and revenue compare to other New York providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. New York median
10 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 80053 | The lab analyst performs a comprehensive metabolic panel, or CMP test in which he measures the blood level of 14 chemicals the code descriptor lists for the panel. | 581 | 590 | 1,160 | $20 | $277.2K |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 173 | 200 | 340 | $40 | $170.7K |
| 87801 | The lab analyst performs a test for multiple infectious agents using amplified nucleic acid probe technique. | 66 | 80 | 240 | $30 | $149.3K |
| 87651 | The lab analyst performs a test for the bacteria Streptococcus, group A, using amplified nucleic acid probe technique. Strep A commonly causes acute pharyngitis, or strep throat. | 259 | 320 | 500 | $30 | $82.6K |
| 87481 | The lab analyst performs a test for Candida species using amplified nucleic acid probe technique. | 83 | 100 | 300 | $30 | $67.5K |
| 88189 | The clinician, typically a pathologist, interprets flow cytometry results of 16 or more markers. | 24 | 30 | 90 | $50 | $47.7K |
| 85025 | A complete blood count (better known as a CBC) is a blood test request by a doctor that provides detailed information about various types of cells in a patient's blood. Usually a pathologist or a… | 837 | 850 | 960 | $1 | $36.4K |
| 87653 | The lab analyst performs a test for Streptococcus, group B, using amplified nucleic acid probe technique. The amplified probe provides a rapid means to assess colonization by Streptococcus, group B,… | 58 | 70 | 300 | $20 | $29.7K |
| 87500 | The lab analyst performs a test for vancomycin resistance in an infectious organism’s nucleic acid using amplified probe technique. VRE, vancomycin resistant enterococcus, is the most common organism… | 9 | 20 | 30 | $20 | $21.4K |
| 87640 | The lab analyst performs the technical lab test to look for Staphylococcus aureus nucleic acid using an amplified probe technique. | 37 | 50 | 210 | $10 | $17.6K |
Other providers in the same ZIP code as Riem Badr, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Long Island Digestive Endoscopy Center, LLC | NY | Ambulatory Surgical Clinic/Center | $1.6M | $1.4M |
| George Cyriac | NY | Hematology & Oncology Physician | $2.7M | $14.5K |
| Amishi Desai | NY | Hematology & Oncology Physician | $2.2M | $431.4K |
| Adriana Guigova | NY | Hematology & Oncology Physician | $2.3M | $46.9K |
| Alfredo Torres Gonzalez | NY | Hematology & Oncology Physician | $1.9M | $16K |
| Joshua Harris | NY | Hematology & Oncology Physician | $1.6M | $62.3K |
| Port Jefferson Asc, LLC | NY | Ambulatory Surgical Clinic/Center | $1.5M | $0 |
| Jerry George | NY | Hematology & Oncology Physician | $1.4M | $59.5K |
| Eric Mitchnick | NY | Urology Physician | $1.2M | $0 |
| Varghese Cherian | NY | Diagnostic Radiology Physician | $976.5K | $155.3K |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.